Developing Novel Antibiotics Consultancy

CARB-X

Antibiotic Resistance

Dame Sally Davies, the Chief Medical Officer (England) said in 2013 that "Antimicrobial resistance poses a catastrophic threat. If we don’t act now, any one of us could go into hospital in 20 years for minor surgery and die because of an ordinary infection that can’t be treated by antibiotics." Further information on the scale of the problem of antibiotic resistance can be found here.

Despite the increasing need for new antibiotics, it is now widely accepted that the antibiotic market is broken and needs new incentives to promote the development of new antibiotics. Despite continuing efforts by many of the key players, it is far from certain that these will be successful.

The Developing Novel Antibiotics Consultancy was started in November 2015 by Professor Richard James to provide advice  to antibiotic developers and potential investors concerning alternatives to traditional small molecule, antibiotic discovery, specifically concentrating on the following areas;

  • Bacteriocins
  • Bacteriophage therapy
  • Rapid genome sequencing of clinical isolates to predict antibiotic resistance

There is developing evidence that these approaches could make a significant contribution to overcoming the problem of antimicrobial resistance by providing an economical way to continually supply effective antibiotics..  

Professor James is a member of the CARB-X/ Advisory Board. He also has extensive experience acting as an Expert Witness in civil disputes; further information can be found here.

The Developing Novel Antibiotics Consultancy carries Professional indemnity, Public and products liability, and Employers' liability insurance.


See my LinkedIn posts on AMR, bacteriocins, phage therapy and COVID-19.